Study guide
19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
Key Takeaways Explain This Topic AI
SOS/VOD after HSCT presents with tender hepatomegaly, weight gain or ascites, and jaundice or rising bilirubin; busulfan, TBI, gemtuzumab, and inotuzumab are high-yield risks.
Baltimore and Seattle criteria are known clinical frameworks; do not treat their numeric cutoffs as ONCC-published exam numbers.
Defibrotide is the disease-specific therapy used for VOD/SOS.
Balance fluid restriction against renal perfusion, avoid hepatotoxins, and know that ursodiol is used for prophylaxis in some centers.
Ultrasound with Doppler supports the diagnosis; distinguish hepatic GVHD, infection, and drug cholestasis.
Last updated: August 2026
CPHON TCO V.D.4 is sinusoidal obstructive syndrome (SOS) , still widely called hepatic veno-occlusive disease (VOD) . The HSCT chapter named the triad and defibrotide ; this page is the emergency algorithm. Endothelial injury in hepatic sinusoids traps cells and debris, sinusoids obstruct, and the liver becomes a tender, congested, portal-hypertensive organ. It is not acute graft-versus-host disease (GVHD) until you have walked the timing and the exam, and it is not a laboratory-only diagnosis you wait on until the bilirubin looks official.
A 4-year-old on day +11 after allogeneic hematopoietic stem cell transplantation (HSCT) with busulfan conditioning, a 9-year-old who received gemtuzumab before transplant, and a teenager with prior inotuzumab for relapsed ALL who now has a rising bilirubin and a tight abdomen are the pictures.
Who is at risk and what you see
Classic timing is the early post-HSCT window (often within the first three weeks, though late SOS exists). High-yield exposures:
- Busulfan myeloablative conditioning
- Total body irradiation (TBI)
- Gemtuzumab (anti-CD33 antibody-drug conjugate)
- Inotuzumab (anti-CD22 antibody-drug conjugate)
- Prior liver injury, second transplant, and very young age on some pathways
What you see: tender hepatomegaly (right-upper-quadrant pain, a liver edge you can feel, a child who guards when you examine), weight gain and ascites from sinusoidal hypertension and third-spacing, and jaundice with a rising bilirubin . Rapid overnight kilograms, a growing abdominal girth, and a child who will not stand because the belly is tight are more useful than waiting for scleral icterus to be obvious in a dim room.
Walk the 4-year-old. Busulfan, day +11, two kilograms up since yesterday, liver tender, bilirubin climbing, urine output slipping. This is SOS/VOD until the team says otherwise. Daily weights, abdominal girth, and a right-upper-quadrant exam are not optional if there is time after meds.
Baltimore and Seattle criteria: name the frameworks
Seattle and Baltimore criteria are known clinical frameworks used in transplant programs to recognize SOS/VOD (combinations of bilirubin rise, hepatomegaly or right-upper-quadrant pain, ascites, and weight gain). You may name them. Do not treat their milligram-per-deciliter or percent-weight cutoffs as if ONCC published them on the CPHON outline. Items test whether you recognize the tender liver plus weight gain plus jaundice cluster after a risk exposure and act, not whether you can recite an adult 1980s table from memory.
Ultrasound with Doppler supports the picture: reversed or reduced portal venous flow, increased hepatic-artery resistance, gallbladder-wall thickening, and ascites. Imaging is supportive , not a license to ignore the exam while you wait for a perfect Doppler sentence. A negative ultrasound does not magically make a tender, gaining, jaundiced day-+12 child fine.
Defibrotide and the fluid-kidney tension
Defibrotide is the disease-specific therapy used for VOD/SOS. It is not a diuretic and not ursodiol. Once the team diagnoses SOS, the nursing job is to get defibrotide started as ordered, watch for bleeding (the drug has antithrombotic endothelial effects), and keep invasive procedures to a minimum.
Supportive care is a tension , not a slogan:
Fluid restriction limits third-spacing into ascites and pulmonary edema.
Renal perfusion still needs enough intravascular volume. The kidney is downstream of abdominal tamponade from ascites and of hepatorenal physiology. Oliguria is a same-hour call, not proof that restriction is working.
Use concentrated medications, daily (or twice-daily) weights, strict intake and output, and abdominal girth. Albumin and diuretics appear on some pathways; they are team tools, not a reflex furosemide race that empties the tank. Avoid hepatotoxins when alternatives exist: extra acetaminophen, unnecessary herbal products, and stacking cholestatic drugs. Calcineurin inhibitors for GVHD prophylaxis are not casually stopped—that is a transplant-team decision because GVHD kills too.
Ursodiol (ursodeoxycholic acid) is used for prophylaxis in some centers . It is center practice, not a universal ONCC-mandated start-on-admission rule. Know that it exists; do not fail an item because a stem asked about prophylaxis rather than treatment. Treatment of established SOS is defibrotide plus supportive care, not more ursodiol as the rescue.
Distinguishing look-alikes
Hepatic GVHD is usually later than classic SOS, more purely cholestatic , and often travels with skin and gut GVHD. Day +12 tender hepatomegaly and three kilograms of ascites is SOS until proven otherwise; day +45 jaundice with a new rash and watery diarrhea is GVHD until proven otherwise. They can overlap. Do not give high-dose steroids as the only move for an early tender liver without considering SOS, and do not give defibrotide for every late bilirubin bump without looking at skin and stool.
Infection: viral hepatitis (including adenovirus, cytomegalovirus, hepatitis viruses), cholangitis, and disseminated fungal disease can raise bilirubin and make the liver tender. Culture, polymerase-chain-reaction panels the team uses, and imaging still belong in the workup.
Drug cholestasis: parenteral nutrition, azole antifungals, and other hepatically cleared drugs cause cholestasis without the rapid weight-gain and ascites packing of SOS. Timing, drugs, and Doppler help. Stopping a hepatotoxin is reasonable; calling every azole bump VOD is not.
A 9-year-old who received gemtuzumab, then TBI-based allogeneic HSCT, who gains 1.5 kg overnight with a tender liver is an SOS page, not a wait-for-Monday hepatology consult. A teenager whose only finding on day +50 is a slow bilirubin rise after a new azole, with a soft nontender abdomen and a gut-skin GVHD rash, is not automatically a defibrotide start.
Feature SOS/VOD Hepatic GVHD Infection Drug cholestasis
Typical clock Early post-HSCT (classically first weeks) Later; often with skin/gut Any time After the offending drug / TPN
Exam Tender hepatomegaly, ascites, weight gain Jaundice; liver often less acutely tender Fever, sepsis, viral signs Often quieter exam
Labs / imaging Rising bilirubin; Doppler supportive Cholestasis Pathogen studies Drug list
Disease-specific therapy Defibrotide GVHD immunosuppression as ordered Directed antimicrobials Stop or switch the drug
Teach families that the liver's small blood channels were injured by conditioning or by gemtuzumab or inotuzumab, that fluid is leaking into the abdomen, and that defibrotide is the medicine aimed at those vessels. Daily weights are treatment, not nagging.
That is TCO V.D.4: name busulfan, TBI, gemtuzumab, and inotuzumab as risk, recognize tender hepatomegaly plus weight gain plus jaundice, use Baltimore and Seattle as named frameworks without treating cutoffs as ONCC numbers, start defibrotide, balance restriction against the kidney, avoid hepatotoxins, know ursodiol prophylaxis exists in some centers, obtain Doppler ultrasound, and tell hepatic GVHD, infection, and drug cholestasis apart.